What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CYTALUX™ (PAFOLACIANINE) INJECTION: folate analog ligand conjugated with an indole cyanine green-like dye. Each subject will be administered a single intravenous dose (0.025 mg/kg) based on their assigned cohort before initiation of intraoperative NIR fluorescent imaging”In the company’s words, NCT07469202 on ClinicalTrials.gov
- Tested for
- Cancer in the Lung, Ovarian Cancer
- Main trialPhase 4
- “The goal of this clinical trial is to learn whether giving Cytalux™ (pafolacianine) injection several days before surgery works as well as giving it closer to the time of surgery for helping surgeons see lesions during an operation. This study is being done in adult patients undergoing surgery for malignant or non-malignant lung lesions or for confirmed ovarian cancer.”In the company’s words, NCT07469202 on ClinicalTrials.gov
- Other names
- pafolacianine injection
Other drugs for Ovarian Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- Mirvetuximab SoravtansineAbbVie · Phase 3
- AzenosertibK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- OregovomabCanariaBio Inc. · Phase 3
- JSKN003Alphamab · JMT-Bio · Phase 3
Coming up1
- 28 May 2027Phase 4 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 9 NovCompletion date moved: 2027-02-28 to 2027-05-28 · ClinicalTrials.gov NCT07469202
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Not yet recruiting | 28 May 2027 | CYTALUX Dose Extension Study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026